What is Avail Pharma?
Originally established in 1998 as the consulting division of AVAIL, Avail Pharma has evolved into a premier consultancy specializing in the pharmaceutical and biotechnological sectors. The company provides high-level analytical and problem-solving services, supported by a network of board-certified medical specialists, former health authority officers, and experienced regulatory writers. By integrating deep industry knowledge with advanced modeling and simulation capabilities, Avail Pharma assists clients in overcoming the multifaceted challenges of drug development and regulatory compliance. Its market position is defined by a commitment to evidence-based strategy and a comprehensive understanding of the life sciences value chain, ensuring that clients can effectively bring innovative therapies to market.
How much funding has Avail Pharma raised?
Avail Pharma has raised a total of $7.1M across 4 funding rounds:
Debt
$125K
Angel/Seed
$750K
Other Financing Round
$2M
Series A
$4.2M
Debt (2013): $125K, investors not publicly disclosed
Angel/Seed (2015): $750K led by Steve Olechowski and Metaprop
Other Financing Round (2017): $2M supported by Charmides Capital, Sandalphon Capital,, Cultivation Capital, and M25 Group
Series A (2020): $4.2M featuring Cultivation Capital
Key Investors in Avail Pharma
Cultivation Capital
Cultivation Capital is a venture capital firm that invests in young companies with transformative ideas across various industries, including life sciences, software, agriculture, and geospatial technology.
Charmides Capital
Charmides Capital is a venture capital firm located in Indiana that specializes in providing seed and Series A stage funding for tech companies in the Midwest.
M25 Group
M25 Group is a London-based firm that has evolved to meet diverse client needs, providing comprehensive services that emphasize order, transparency, and logistical efficiency.
What's next for Avail Pharma?
With the recent infusion of capital, Avail Pharma is well-positioned to expand its service offerings and deepen its footprint in the global biotech consulting arena. The company is expected to prioritize the enhancement of its digital infrastructure and the expansion of its multidisciplinary expert network to meet the increasing demand for sophisticated pharmacogenomic analysis and regulatory navigation. As the firm moves into its next phase of growth, the focus will likely remain on scaling its strategic advisory capabilities to support larger, more complex international clinical programs, thereby reinforcing its role as a vital partner for pharmaceutical innovators worldwide.
See full Avail Pharma company page
